Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

被引：0

作者：

Vogel, Arndt

Chan, Stephen Lam

Ren, Zhenggang

Bai, Yuxian

Gu, Shanzhi

Lin, Xiaoyan

Chen, Zhendong

Jia, Weidong

Jin, Yongdong

Guo, Yabing

Hu, Xiaohua

Sultanbaev, Alexander Valerievich

Pazgan-Simon, Monika

Pisetska, Margaryta

Nip, Tsz Keung

Zhang, Haisong

Du, Jinghua

Cheng, Ann-Lii

Kaseb, Ahmed Omar

Qin, Shukui

机构：

[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[3] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Hepat Oncol, Shanghai, Peoples R China

[4] Harbin Med Univ, Dept Gastroenterol, Canc Hosp, Harbin, Peoples R China

[5] Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China

[6] Fujian Med Univ, Dept Oncol, Union Hosp, Fuzhou, Peoples R China

[7] Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei, Peoples R China

[8] Anhui Prov Hosp, Dept Gen Surg, Hefei, Peoples R China

[9] UESTC, Sichuan Canc Hosp & Inst, Dept Med Oncol, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China

[10] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Liver Canc Ctr, Guangzhou, Peoples R China

[11] Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning, Peoples R China

[12] State Autonomous Budgetary Healthcare Inst, Republican Clin Oncol Dispensary, MoH Republ Bashkortostan, Ufa, Russia

[13] Wroclaw Med Univ, Dept Infect Dis & Hepatol, Wroclaw, Poland

[14] Cent Badan Klinicznych P Napora, Wroclaw, Poland

[15] Communal Non Profit Enterprise Reg Ctr Oncol, Dept Liver & Pancreas Gland Oncosurg, Kharkiv, Ukraine

[16] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Jiangsu, Peoples R China

[17] Natl Taiwan Univ Hosp, Taipei, Taiwan

[18] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX, Peoples R China

[19] Canc Ctr Nanjing, Jinling Hosp, Nanjing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4110

引用

页数：1

共 50 条

[41] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
Yau, T.
Galle, P. R.
Decaens, T.
Sangro, B.
Qin, S.
Park, J-W.
Ikeda, M.
Tai, D. W. M.
Chiu, C-F.
Chon, H. J.
Kang, Y-K.
Hiraoka, A.
Huang, Y-H.
Lee, T-Y.
Numata, K.
Yamashita, T.
Ogata, T.
Hreiki, J.
Lu, Y.
Kudo, M.
ANNALS OF ONCOLOGY, 2024, 35 : S1450 - S1451
[42] Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
Hong, Shaodong
Zhang, Yaxiong
Yu, Gengsheng
Peng, Peijian
Peng, Jiewen
Jia, Jun
Wu, Xuan
Huang, Yan
Yang, Yunpeng
Lin, Qing
Xi, Xuping
Xu, Mingjun
Chen, Dongping
Lu, Xiaojun
Wang, Rensheng
Cao, Xiaolong
Chen, Xiaozhong
Lin, Zhixiong
Xiong, Jianping
Lin, Qin
Xie, Conghua
Li, Zhihua
Pan, Jianji
Li, Jingao
Wu, Shixiu
Lian, Yingni
Yang, Quanlie
Zhao, Chong
Fang, Wenfeng
Zhang, Li
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (29) : 3273 - +
[43] Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Chan, S. L.
Sangro, B.
Kelley, R. K.
Lau, G.
Kudo, M.
Sukeepaisarnjaroen, W.
De Toni, E. N.
Furuse, J.
Kang, Y-K.
Galle, P. R.
Rimassa, L.
Heurgue, A.
Tam, V. C.
Dao, T. V.
Thungappa, S. Chiradoni
Breder, V.
Ostapenko, Y. V.
Reig Monzon, M. E.
Gupta, C.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2023, 34 : S1530 - S1531
[44] First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study
Ying Liu
Han Yue
Shuning Xu
Feng Wang
Ning Ma
Ke Li
Lei Qiao
Jufeng Wang
International Journal of Clinical Oncology, 2015, 20 : 952 - 959
[45] First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study
Liu, Ying
Yue, Han
Xu, Shuning
Wang, Feng
Ma, Ning
Li, Ke
Qiao, Lei
Wang, Jufeng
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 952 - 959
[46] Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC)
Alsina, Angel
Kudo, Masatoshi
Vogel, Arndt
Cheng, Ann-Lii
Tak, Won Young
Ryoo, Baek-Yeol
Evans, T. R. Jeffry
Lopez, Carlos Lopez
Daniele, Bruno
Blanc, Jean-Frederic
Ren, Min
Baldwin, Rae Lynn
Izumi, Namiki
Qin, Shukui
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[47] Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study
Liu, Lulu
Wang, Lei
Ding, Yiling
Zhang, Qilin
Shu, Yamin
BMJ OPEN, 2025, 15 (03):
[48] Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database
Kaplan, David E.
Tan, Ruoding
Xiang, Cheryl
Mu, Fan
Hernandez, Sairy
Ogale, Sarika
Li, Jiayang
Lin, Yilu
Shi, Lizheng
Singal, Amit G.
CANCERS, 2024, 16 (20)
[49] Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study
Zhang, Cheng-Sheng
Zeng, Zhi-Ming
Zhuo, Man-Yun
Luo, Jing-Ru
Zhuang, Xiao-Hong
Xu, Jun-Nv
Zeng, Jie
Ma, Jie
Lin, Hai-Feng
ONCOLOGIST, 2023, : e1239 - e1247
[50] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Kudo, Masatoshi
Finn, Richard S.
Qin, Shukui
Han, Kwang-Hyub
Ikeda, Kenji
Piscaglia, Fabio
Baron, Ari
Park, Joong-Won
Han, Guohong
Jassem, Jacek
Blanc, Jean Frederic
Vogel, Arndt
Komov, Dmitry
Evans, T. R. Jeffry
Lopez, Carlos
Dutcus, Corina
Guo, Matthew
Saito, Kenichi
Kraljevic, Silvija
Tamai, Toshiyuki
Ren, Min
Cheng, Ann-Lii
LANCET, 2018, 391 (10126): : 1163 - 1173

← 1 2 3 4 5 →